Preclinical studies indicate that GLP-1 RAs may reduce the reinforcing effects of substances such as nicotine, alcohol, opioids, and cocaine
1 However, the introduction of Wegovy 7.2 mg means both medications support similar weight loss at their highest dose
While liraglutide has demonstrated CV benefits in high-risk patients through trials such as LEADER [34], its effect sizes often appear less pronounced than those reported for semaglutide
it'll need some tweaks and adjustments along the way, but Id call it a rock-solid start
If central dopamine suppression is responsible, pro-dopaminergic agents like flibanserin or bremelanotide, both FDA-approved for hypoactive sexual desire disorder in premenopausal women, represent potential solutions